Trial · NCT01639157

Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine

NCT01639157, Not applicable, Completed, William Stoops; results first posted 2016-02-19

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine. Trials, record NCT01639157. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01639157

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine
NCT number: NCT01639157
Status: Completed
Phases: Not applicable
Enrollment: 9 participants, actual
Lead sponsor: William Stoops
Conditions: Cocaine Use Disorders
Interventions: Buspirone, Placebo
First posted: 2012-07-12
Last updated: 2016-02-19
Results first posted: 2016-02-19

Source ClinicalTrials.gov

Registered outcomes27

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative	One test per cocaine dose level per intervention for each participant over his/her 2 week inpatient admission	The reinforcing effects of cocaine were determined using a modified progressive ratio procedure (Stoops et al., 2010) in which subjects made 6 choices between available each available cocaine dose and money (US$0.25). Reinforcing effects are measured for each cocaine dose during both buspirone and placebo maintenance.
Secondary	Peak Score on Sedative Subscale of the Adjective Rating Scale	Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	Subjects completed 16 items that loaded into the Sedative Subscale of the Adjective Rating Scale. The items were rated 0-4 on a Likert-type scale and the sum for the 16 "sedative" items was summed to yield the Sedative Subscale score. The maximum score for this scale was 64, the minimum was 0. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.
Secondary	Peak Systolic Blood Pressure	This measure was completed at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	Systolic blood pressure was measured with an automated monitor. Higher values represent greater systolic pressure. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.
Secondary	Peak Score on Stimulant Subscale of the Adjective Rating Scale	Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	Subjects completed 16 items that loaded into the Stimulant Subscale of the Adjective Rating Scale. The items were rated 0-4 on a Likert-type scale and the sum for the 16 "sedative" items was summed to yield the Stimulant Subscale score. The maximum score for this scale was 64, the minimum was 0. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.
Secondary	Peak Ratings of "Active, Alert, Energetic" on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	Subjects rated their feelings of "Active, Alert, Energetic" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.
Secondary	Peak Ratings of "Any Effect" on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	Subjects rated their feelings of "Any Effect" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.
Secondary	Peak Ratings of "Bad Effects" on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	Subjects rated their feelings of "Bad Effects" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.
Secondary	Peak Ratings of "Euphoric" on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	Subjects rated their feelings of "Euphoric" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.
Secondary	Peak Ratings of "Good Effects" on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	Subjects rated their feelings of "Good Effects" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.
Secondary	Peak Ratings of "High" on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	Subjects rated their feelings of "High" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.

1 to 10 of 27Source ClinicalTrials.gov

See all 27 registered outcomes

Outcomes27

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative	One test per cocaine dose level per intervention for each participant over his/her 2 week inpatient admission	Number of Cocaine Choices	MEAN
SECONDARY	Peak Score on Sedative Subscale of the Adjective Rating Scale	Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	arbitrary units on a Likert-type scale	MEAN
SECONDARY	Peak Systolic Blood Pressure	This measure was completed at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	mmHg	MEAN
SECONDARY	Peak Score on Stimulant Subscale of the Adjective Rating Scale	Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	arbitrary units on a Likert-type scale	MEAN
SECONDARY	Peak Ratings of Active, Alert, Energetic on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	arbitary units on a Visual Analog Scale	MEAN
SECONDARY	Peak Ratings of Any Effect on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	arbitary units on a Visual Analog Scale	MEAN
SECONDARY	Peak Ratings of Bad Effects on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	arbitary units on a Visual Analog Scale	MEAN
SECONDARY	Peak Ratings of Euphoric on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	arbitary units on a Visual Analog Scale	MEAN
SECONDARY	Peak Ratings of Good Effects on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	arbitary units on a Visual Analog Scale	MEAN
SECONDARY	Peak Ratings of High on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.	arbitary units on a Visual Analog Scale	MEAN

1 to 10 of 27Source ClinicalTrials.gov

See all 27 outcomes

Results by group162

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative	Buspirone	0 mg Cocaine	1.00	Standard Error 0.707	Number of Cocaine Choices
Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative	Placebo	0 mg Cocaine	1.22	Standard Error 0.813	Number of Cocaine Choices
Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative	Buspirone	15 mg Cocaine	5.56	Standard Error 0.338	Number of Cocaine Choices
Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative	Placebo	15 mg Cocaine	5.33	Standard Error 0.441	Number of Cocaine Choices
Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative	Buspirone	45 mg Cocaine	5	Standard Error .289	Number of Cocaine Choices
Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative	Placebo	45 mg Cocaine	4.89	Standard Error .455	Number of Cocaine Choices
Peak Score on Sedative Subscale of the Adjective Rating Scale	Buspirone	0 mg Cocaine	2.9	Standard Error 1.3	arbitrary units on a Likert-type scale
Peak Score on Sedative Subscale of the Adjective Rating Scale	Placebo	0 mg Cocaine	3.6	Standard Error 1.6	arbitrary units on a Likert-type scale
Peak Score on Sedative Subscale of the Adjective Rating Scale	Buspirone	15 mg Cocaine	4.4	Standard Error 1.7	arbitrary units on a Likert-type scale
Peak Score on Sedative Subscale of the Adjective Rating Scale	Placebo	15 mg Cocaine	4.8	Standard Error 1.8	arbitrary units on a Likert-type scale

1 to 10 of 162Source ClinicalTrials.gov

See all 162 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Buspirone Then Placebo	4
Overall Study	STARTED	Placebo Then Buspirone	5
Overall Study	COMPLETED	Buspirone Then Placebo	4
Overall Study	COMPLETED	Placebo Then Buspirone	5
Overall Study	NOT COMPLETED	Buspirone Then Placebo	0
Overall Study	NOT COMPLETED	Placebo Then Buspirone	0

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Buspirone
Total, all-cause mortality	Placebo
Total, other adverse events	Buspirone	0	9
Total, other adverse events	Placebo	0	9
Total, serious adverse events	Buspirone	0	9
Total, serious adverse events	Placebo	0	9

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
20638380	BACKGROUND

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R21DA034095	A Human Laboratory Study to Investigate Buspirone for Cocaine Use Disorders	STOOPS, WILLIAM WALTON	UNIVERSITY OF KENTUCKY	NATIONAL INSTITUTE ON DRUG ABUSE	2012 to 2013

Source NIH RePORTER

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Buspirone vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01639157

GET https://conductscience.org/api/trials/v1/NCT01639157/registered?page=2

API reference For AI assistants